Abbott Laboratories (ABT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Abbott Laboratories (ABT) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How ABT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | 56.4% | 18.2% | $6.52B | $7.39B | 11.9% |
| FY 2024 | $41.95B | 55.4% | 16.3% | $13.40B | $6.35B | 10.2% |
| FY 2023 | $40.11B | 44% | 16.2% | $5.72B | $5.46B | 8.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ABT)
- ✓Live walkthrough of ABT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ABT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.
ABT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Abbott Laboratories (ABT)?
In FY 2025 (10-K), ABT converted $44.3B of revenue into a 56.4% gross margin, 18.2% operating margin, and $7.4B in free cash flow (16.7% FCF margin).